摘要
目的探讨顺铂联合培美曲塞治疗表皮生长因子受体(EGFR)突变晚期非小细胞肺腺癌(NSCLC)的临床疗效。方法根据治疗方案将112例EGFR突变晚期NSCLC患者分为观察组(n=57)和对照组(n=55),对照组患者接受顺铂+吉西他滨治疗,观察组患者接受顺铂+培美曲塞治疗。比较两组患者的总有效率、疾病控制率、总生存期(OS)、无进展生存期(PFS)和不良反应情况。结果观察组患者的疾病控制率为73.68%,高于对照组患者的54.55%,差异有统计学意义(P﹤0.05);观察组患者的总有效率为43.86%,高于对照组患者的29.09%,差异无统计学意义(P﹥0.05)。治疗前和治疗后3个月,两组患者CEA、CA125和VEGF水平比较,差异均无统计学意义(P﹥0.05)。治疗后3个月,两组患者CEA、CA125和VEGF水平均低于本组治疗前,差异均有统计学意义(P﹤0.05)。观察组患者的中位PFS为15.00个月长于对照组患者的12.00个月;观察组患者中位OS为22.00个月长于对照组的17.00个月,差异有统计学意义(P﹤0.05)。两组患者中性粒细胞减少、贫血、血小板减少、胃肠道反应和肝肾功能损害发生率的比较,差异均无统计学意义(P﹥0.05)。结论顺铂联合培美曲塞治疗EGFR突变晚期NSCLC疗效较好,且安全可耐受。
Objective To investigate the clinical effect of cisplatin combined with pemetrexed in the treatment of advanced non-small cell lung adenocarcinoma(NSCLC)with epidermal growth factor receptor(EGFR)mutation.Method A total of 112 patients with advanced NSCLC with EGFR mutation were divided into study group(n=57)and control group(n=55),the control group patients were given cisplatin+gemcitabine,while those in the study group were administered with cisplatin+pemetrexed,the overall response rate(ORR),disease control rate(DCR),overall survival(OS),progression-free survival(PFS)and adverse reactions were observed in both groups.Result The DCR was 73.68%in study group versus 54.55%in control group,and the difference was statistically significant(P<0.05);the ORR of the observation group was 43.86%,which was higher than that of the control group 29.09%(P>0.05).Before treatment and 3 months after treatment,the CEA,CA125 and VEGF levels were similar between the two groups(P>0.05).In 3 months after treatment,the CEA,CA125 and VEGF levels were decreased evidently(P<0.05).The median PFS in study group was 15.00 months,which was longer compared to the 12.00 months in control group,with statistically significant difference observed(P<0.05).The median OS in study group was 22.00 months,and it was extended compared to the 17.00 months in control group(P<0.05).The incidences of neutropenia,anemia,thrombocytopenia,gastrointestinal reactions and hepatic and renal impairment were comparable between the two groups(P>0.05).Conclusion Cisplatin combined with pemetrexed demonstrates fairly good clinical efficacy in the treatment of advanced NSCLC with EGFR mutation,with acceptable safety and tolerance.
作者
陈东堂
冉秀荣
CHEN Dongtang;RAN Xiurong(Department of Pharmacy,the Third People’s Hospital of Shangqiu,Shangqiu 476000,He’nan,China;Department of General Medicine,the First People’s Hospital of Shangqiu,Shangqiu 476000,He’nan,China)
出处
《癌症进展》
2020年第11期1144-1147,共4页
Oncology Progress
关键词
非小细胞肺腺癌
顺铂
培美曲塞
表皮生长因子受体
non-small cell lung adenocarcinoma
cisplatin
pemetrexed
epidermal growth factor receptor
